Metformin as a Tool to Target Aging

By Nir Barzilai, J. Crandall, Stephen B. Kritchevsky, Mark A. Espeland. Cell Metabolism, 2016

967 citations recorded by the source corpus.

Aging has been targeted by genetic and dietary manipulation and by drugs in order to increase lifespan and health span in numerous models. Metformin, which has demonstrated protective effects against several age-related diseases in humans, will be tested in the TAME (Targeting Aging with Metformin) trial, as the initial step in the development of increasingly effective next-generation drugs.

Subfields: Molecular Biology, Physiology, Surgery

View Paper: https://www.semanticscholar.org/paper/506ad990f2fec24879a5c7cad28f819165543695

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. T. Arumugam
2. Traci E LaMoia
3. Gerald I. Shulman
4. Sriram Gubbi
5. Ameya Sadguru Kulkarni
6. Nir Barzilai
7. F. Farzaneh
8. K. Uchida

In Physiology

1. T. Arumugam
2. Jun Yoshino
3. S. Imai
4. Gerald I. Shulman
5. Nir Barzilai
6. Mark P. Mattson
7. C. Bailey
8. V. Samuel

In Surgery

1. Traci E LaMoia
2. Gerald I. Shulman
3. Mark P. Mattson
4. C. Bailey

Citations in the corpus

• Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice (2016, positive): “Ce aging healthy and prevent expensive age-associated health problems, efforts to develop effective, affordable, anti-aging interventions have recently been intensified, leading to some promising compounds, such as metformin, rapamycin, and SIRT1 activators (Barzilai et al., 2016; Hubbard and Sincla”
• Cellular and Molecular Mechanisms of Metformin Action (2020, background): “The cancer field has begun to explore the antitumor effect of metformin as a potential treatment for certain cancers (23, 24), and the first trials of metformin for treating aging in healthy humans are currently underway (25, 26).”
• Epigenetic clock analysis of diet, exercise, education, and lifestyle factors (2017, neutral): “Metformin, which is a first-line medication for the treatment of type 2 diabetes, has garnered substantial interest by aging researchers [87].”
• Benefits of Metformin in Attenuating the Hallmarks of Aging (2020, background): “Association studies suggest a decrease in the incidence of most age-related cancers, Alzheimer’s Disease while clinical studies support metformin’s role in a decrease in cognitive decline and reduced mortality in diabetics taking metformin compared to non-diabetics (Barzilai et al. 2016).”
• Mechanisms of Vascular Aging (2018, methodology): “There is currently an aging clinical trial, TAME (Targeting Aging With Metformin), that aims to determine whether metformin can delay the onset of age-related diseases in humans.(187) In the context of vascular aging, AMPK was shown to confer vasoprotective effects, augmenting eNOS activation.”
• Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention (2019, background): “It is a drug, typically administrated in type 2 diabetes but proposed as an antiaging molecule for humans, such as the study called “Targeting Aging with Metformin” (94).”
• Metformin: historical overview (2017, background): “Advances in pharmacogenomics may better inform responsiveness to metformin and effects on the gut microbiome, and animal studies have intriguingly noted anti-ageing effects of metformin [90, 91].”
• Hallmarks of Brain Aging: Adaptive and Pathological Modification by Metabolic States (2018, background): “cades, inhibits liver glucose production, but also activates multiple cellular pathways that counteract aging processes, including activation of AMPK and inhibition of mTOR and inflammatory pathways (Barzilai et al., 2016).”